AbbVie Inc. $ABBV Stake Trimmed by ProShare Advisors LLC

Posted by Brian Himes on Nov 1st, 2026

ProShare Advisors LLC cut its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 12.2% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 942,552 shares of the company’s stock after selling 130,829 shares during the period. ProShare Advisors LLC owned approximately 0.05% of AbbVie worth $246,562,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vise Technologies Inc. boosted its position in AbbVie by 21.7% during the third quarter. Vise Technologies Inc. now owns 143,948 shares of the company’s stock worth $37,655,000 after acquiring an additional 25,704 shares during the last quarter. Investment Partners LTD. lifted its holdings in shares of AbbVie by 82.2% in the 3rd quarter. Investment Partners LTD. now owns 10,925 shares of the company’s stock worth $2,858,000 after acquiring an additional 4,928 shares during the last quarter. Global Assets Advisory LLC boosted its position in shares of AbbVie by 1.7% during the third quarter. Global Assets Advisory LLC now owns 7,625 shares of the company’s stock worth $2,008,000 after buying an additional 126 shares during the period. Summit Global Investments lifted its position in shares of AbbVie by 45.1% during the third quarter. Summit Global Investments now owns 16,792 shares of the company’s stock worth $4,393,000 after purchasing an additional 5,220 shares in the last quarter. Finally, Coyle Financial Counsel LLC grew its stake in AbbVie by 3.1% during the 3rd quarter. Coyle Financial Counsel LLC now owns 8,020 shares of the company’s stock worth $2,098,000 after purchasing an additional 240 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Up 1.4%

Shares of AbbVie stock opened at $294.80 on Friday. The stock has a market capitalization of $520.85 billion, a P/E ratio of 50.74, a PEG ratio of 1.35 and a beta of 0.24. The stock has a 50 day moving average price of $269.35 and a two-hundred day moving average price of $237.23. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $298.74.

AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings data on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, topping the consensus estimate of $3.73 by $0.09. The firm had revenue of $17.40 billion for the quarter, compared to analysts’ expectations of $17.32 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.86 earnings per share. Sell-side analysts anticipate that AbbVie Inc. will post 13.92 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s payout ratio is presently 195.48%.

Analyst Ratings Changes

A number of brokerages have recently commented on ABBV. BMO Capital Markets lifted their target price on shares of AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. Barclays upped their target price on AbbVie from $300.00 to $325.00 and gave the company an “overweight” rating in a research report on Wednesday, October 21st. Bank of America reaffirmed a “buy” rating on shares of AbbVie in a research report on Tuesday, September 8th. Finally, Cantor Fitzgerald increased their price target on AbbVie from $285.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus price target of $279.86.

View Our Latest Analysis on AbbVie

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Q3 results beat expectations. Adjusted earnings per share were $3.82 versus the $3.73 analyst consensus, while revenue rose 10.3% year over year to $17.404 billion, ahead of the $17.32 billion estimate. Adjusted EPS more than doubled from the prior-year quarter. AbbVie Reports Third-Quarter 2026 Financial Results
Positive Sentiment: Immunology and neuroscience provided strong momentum. Skyrizi generated $5.776 billion in revenue and Rinvoq produced $2.706 billion, helping immunology revenue increase 16.3%. Neuroscience revenue climbed 19.4%, led by Vraylar, therapeutic Botox, Ubrelvy and Qulipta. AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
Positive Sentiment: Management raised guidance and its dividend. AbbVie increased its 2026 adjusted EPS outlook to $13.95–$13.99 from $13.76–$13.96, despite including $0.69 per share of year-to-date acquired in-process research and development and milestone expenses. The company also announced a 5.2% dividend increase beginning with the February 2027 payment. AbbVie Raises FY26 Adjusted EPS Outlook and Boosts Dividend
Positive Sentiment: Pipeline expansion supports longer-term confidence. AbbVie completed its acquisition of Apogee Therapeutics, strengthening its immunology pipeline, while Qulipta also outperformed topiramate in a Phase 3 migraine-prevention study. AbbVie QULIPTA Phase 3 Migraine Prevention Trial
Negative Sentiment: Investors remain focused on valuation and concentration risks. Humira revenue fell 31.2% to $683 million, while aesthetics revenue declined 1.4%. After a substantial multiyear rally and trading near its 52-week high, analysts question whether additional valuation expansion is justified and how effectively AbbVie can sustain growth beyond Skyrizi and Rinvoq. Skyrizi and Rinvoq Dominate AbbVie Q3

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 0.06% of the company’s stock.

AbbVie Profile

(Free Report)

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.